P2Y Receptor Agonist

MRS2690 is a selective P2Y14 receptor agonist. MRS2690 inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 induces intracellular calcium mobilization, activates P38 and stimulates [³⁵S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690can be used for ischemic heart disease.

MRS2693 trisodium is a selective P2Y6 agonist with an EC₅₀ value of 0.015 μM. MRS2693 trisodium can reduce the activation of NF-kappaB and activate the ERK1/2 pathway, and has a cytoprotective effect on mouse hindlimb skeletal muscle ischemia-reperfusion injury model.

UDP-GlcNAc (UDP-N-Acetyl-D-glucosamine) is an important component and precursor of bacterial peptidoglycan. UDP-GlcNAc is a nucleotide sugar used by Glycosyltransferases to synthesize glycoproteins, glycosaminoglycans, glycolipids, and glycoRNA. UDP-GlcNAc also serves as the donor substrate for forming O-GlcNAc, a dynamic intracellular protein modification involved in diverse signaling and disease processes. UDP-GlcNAc is the sugar nucleotide donor for the synthesis of O-GlcNAc modified proteins. UDP-GlcNAc also acts as a full agonist of the P2Y₁₄ receptor and inhibits the formation of cAMP. UDP-GlcNAc can be used in studies related to bacterial infections.

Uridine 5'-O-thiodiphosphate (UDP-β-S) is a P2Y₆ receptor agonist with an EC₅₀ of 25 nM. Uridine 5'-O-thiodiphosphate resists degradation by extracellular nucleotidases and stimulates the accumulation of inositol phosphates. Uridine 5'-O-thiodiphosphate stimulates contractile responses in endothelium-denuded rat mesenteric arteries. As a mitogen, Uridine 5'-O-thiodiphosphate stimulates DNA synthesis, [³H] thymidine incorporation, protein synthesis, [³H]leucine incorporation, and increases the number of vascular smooth muscle cells. Uridine 5'-O-thiodiphosphate can be used in the research of cardiovascular diseases such as atherosclerosis.

2-MeS-ATP (2-Methylthio-ATP) is an analog of adenosine nucleotides and acts as a P2Y purinergic receptor agonist specific for adenosine nucleotide activation. 2-MeS-ATP is also able to inhibit the release of toxic mediators from macrophages stimulated by endotoxin (LPS). 2-MeS-ATP can be used in the study of endotoxin shock and inflammatory diseases.

2-Thio-UTP is a selective P2Y₂ inhibitor with an EC₅₀ value of 50 nM. 2-Thio-UTP reduces pro-fibrotic gene expression and protein α-smooth muscle actin. 2-Thio-UTP has the potential for the research of calcific aortic valve stenosis (CAVS) .

ATPγS tetralithium salt (Standard) is the analytical standard of ATPγS (tetralithium salt) (HY-108666). This product is intended for research and analytical applications. ATPγS (tetralithium salt) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATPγS (tetralithium salt) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATPγS (tetralithium salt) is active in ATP hydrolysis.

5'-UMPS (Uridine-5'-O-monophosphorothioate) is a P2Y14 receptor agonist. 5'-UMPS can induce HeLa cell growth slightly.

4-Thiouridine 5′-triphosphate (4-Thio-UTP) tetralithium (Compound 15) is a UTP analog and potent P2Y₂ and P2Y₄ agonist with EC₅₀ values of 35 and 350 nM for hP2Y₂ and hP2Y₄, respectively. 4-Thiouridine 5′-triphosphate tetralithium can be used in cross-linking experiments and transcriptional complex labeling studies.

MRS2905 (α,β-Methylene-2-thio-UDP) trisodium is a selective P2Y14R agonist with an EC₅₀ of 0.92 nM. MRS2905 trisodium is inactive at the UDP-activated P2Y6 receptor, and at other P2Y receptors.